Sharemaestro Newsreel

Abeona Therapeutics earnings missed by $0.13, revenue fell short of estimates

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Given Average Recommendation of "Moderate Buy" by Brokerages

Polaryx Therapeutics (NASDAQ:PLYX) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $7.67 against a current share price of $2.48. Insider ownership is significant at 45.82%, and CEO Alex Keun Mo Yang recently purchased 88,453 shares. The …

Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp

Citizens Jmp has reduced its price target for Spruce Biosciences (NASDAQ:SPRB) to $144.00 from $150.00 but maintained a "market outperform" rating, indicating a potential upside of nearly 199%. Despite a wider-than-expected quarterly loss of $6.68 per share, analyst sentiment remains largely positive with a …

Longeveron Inc. (LGVN) investors disclose 9% beneficial stake through warrant holdings

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have filed an amended Schedule 13G, disclosing a beneficial ownership of approximately 9.0% in Longeveron Inc.'s Class A common stock. This stake, totaling 2,941,180 shares, is primarily held through warrants exercisable by Intracoastal Capital. …

ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings

ArriVent BioPharma (NASDAQ:AVBP) experienced a 4.7% drop in share price after reporting weaker-than-expected quarterly earnings, missing analyst estimates by $0.06 with a $1.05-per-share loss. Despite the share price decline and significantly lower trading volume, analyst sentiment remains largely positive, holding a "Moderate Buy" consensus …

Kyverna Therapeutics advances autoimmune drug mivocabtagene autoleucel with strong trial results and regulatory progress.

Kyverna Therapeutics is making significant progress with its autoimmune drug, mivocabtagene autoleucel, showing strong trial results where all 26 patients stopped chronic immunotherapies and most reported improved mobility. The company is pursuing a rolling Biologics License Application, aiming for completion by late 2026 and …

Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a 4.8% beneficial ownership stake in Artelo Biosciences (ARTL) through a warrant held by Intracoastal. This ownership amounts to 173,914 shares of common stock, issuable upon the warrant's exercise, and is based …

AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a passive ownership stake of 5.82% in Vanda Pharmaceuticals Inc. (VNDA), amounting to 3,497,695 shares. The SEC filing, a Schedule 13G, indicates that these entities have shared voting power over 3,313,298 shares …

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages

Vanda Pharmaceuticals (NASDAQ:VNDA) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $13.70 despite recent reductions from some analysts. The company reported a larger-than-expected quarterly loss and missed revenue estimates, leading analysts to anticipate unprofitability for …

Invus reports 8.0% stake in Scholar Rock (SRRK) through 9.6M shares

Invus Public Equities, L.P. and associated entities have reported an 8.0% beneficial ownership stake in Scholar Rock Holding Corporation (SRRK), totaling 9,575,013 shares of common stock. This is detailed in an amended Schedule 13G filing, which states that the shares were acquired for passive …

Abivax S.A. (ABVX) investors report 6.0% beneficial stake via Invus entities

Invus Public Equities, L.P. and affiliated entities, including Avicenna Life Sci Master Fund LP, have collectively reported a 6.0% beneficial ownership in Abivax S.A. (ABVX) as of June 30, 2026. This stake, comprising Ordinary Shares and American Depositary Shares, totals 4,825,759 shares attributed to …

MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M

MiNK Therapeutics reported a narrowed net loss of $3.1 million for Q2 2026, an improvement from $4.2 million year-over-year, and ended the quarter with $8.8 million in cash. The company advanced its Agent 797 into a Phase 2 trial for acute lung injury and …

ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts

Argus has raised its target price for ACADIA Pharmaceuticals Inc. (ACAD) to $31.00, up from its previous rating. The biopharmaceutical company focuses on developing and commercializing medicines for central nervous system (CNS) disorders and rare diseases. This report, published on August 12, 2026, highlights …

CorMedix (NASDAQ:CRMD) Shares Gap Up Following Earnings Beat

CorMedix (NASDAQ:CRMD) shares gapped up after reporting strong quarterly earnings, with EPS of $0.29 beating expectations of $0.24 and revenue of $101.93 million exceeding the $96.04 million consensus. The stock opened at $8.39, up from its previous close of $7.10, and traded around $8.76. …

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings

Zenas BioPharma (NASDAQ:ZBIO) experienced a 6.6% stock price drop after reporting disappointing quarterly earnings, with an EPS of $(1.77) against an estimated $(1.12) and revenue of $1 million against a $15 million forecast. Despite the earnings miss, analysts generally maintain a "Moderate Buy" rating …

MeiraGTx (NASDAQ:MGTX) Shares Gap Up on Strong Earnings

Pharvaris (NASDAQ:PHVS) Given New $75.00 Price Target at Citizens Jmp

Valneva (VALN) revenue drops 33% while Lyme vaccine advances toward filings

Celcuity earnings loom as breast cancer drug approval fuels optimism By Investing.com

Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?

Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite …

Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings

Molecular Partners AG (MOLNZ.XC) stock price, news, quote and history

Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock

Marshall Fordyce, CEO of Vera Therapeutics, sold $679,747 worth of Class A Common Stock on May 12, 2026, after exercising stock options. These transactions were executed under a pre-arranged trading plan, and he now directly owns 235,244 shares and holds 590,551 stock options. The …

Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock

Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 46,250 shares of the company’s Class A Common Stock for approximately $1.96 million on July 7, 2026, while concurrently acquiring the same number of shares through stock option exercises. The sales were conducted …

Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise

Vera Therapeutics' President and CEO, Marshall Fordyce, exercised options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares on June 23, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on January …

Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan

Vera Therapeutics (VERA) CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares in open-market transactions on May 12, 2026. The sales, totaling approximately $680K in gross proceeds, were executed …

Abeona stock drops after Q2 revenue miss (ABEO:NASDAQ)

J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46

J.P. Morgan has reiterated its Buy rating on Olema Pharmaceuticals (OLMA.US) and set a price target of $46. This indicates a positive outlook from the firm regarding the company's future performance.

Entolimod Could Receive Its First National Registration in Ukraine

Valion Bio (Nasdaq: VBIO) announced that Ukraine's Ministry of Health has accepted the regulatory dossier for its ARS countermeasure, Entolimod, for formal review. A favorable decision, which could come as early as Q4 2026, would mark Entolimod's first national registration and could lead to …

Iovance (IOVA) Q2 2026 Earnings Call Transcript

Iovance Biotherapeutics reported record Q2 2026 revenue of $99.3 million, a 66% year-over-year increase, driven by strong Amtagvi demand and achieving a 56% gross margin. The company is expanding its TIL therapy platform into broader solid tumor indications like non-small cell lung cancer and …

GeoVax Labs, Inc. (GOVX) holders cap ownership at 4.99% with warrants

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively reported a 4.99% beneficial ownership in GeoVax Labs, Inc. (GOVX) as of June 2026, totaling 273,657 shares derived from exercisable warrants. This stake is capped at 4.99% due to blocker provisions in additional …

Piper Sandler raises First Tracks stock price target on pipeline progress

CG Oncology (CGON) Faces A Fair Value Gap Following Its Latest Earnings

CG Oncology recently reported its Q2 and H1 2026 earnings, showing revenue of US$1.16 million for the quarter and a net loss of US$79.06 million. Despite being a loss-making company, a discounted cash flow (DCF) model by Simply Wall St estimates a fair value …

Earnings call transcript: MediWound tops Q2 2026 revenue forecast as shares rise

MediWound Ltd. (MDWD) exceeded Q2 2026 revenue forecasts, reporting $3.1 million against an expected $2.89 million, leading to a 1.87% rise in pre-market shares. The company reaffirmed its full-year 2026 revenue guidance of $24 million to $26 million, anticipating stronger performance in the second …

Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb

Cytokinetics has filed a lawsuit against Bristol-Myers Squibb and MyoKardia, seeking a declaratory judgment that it does not infringe on U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The company also seeks an injunction to prevent infringement litigation related to its …

Fennec Pharmaceuticals (FENC) gains 9.6% stakeholder via Rosalind Advisors

Rosalind Advisors Inc. and related parties have reported a 9.6% beneficial ownership stake in Fennec Pharmaceuticals Inc. (FENC), holding 3,321,333 common shares. This ownership includes shares held by Rosalind Master Fund L.P., and involves shared voting and dispositive power among Rosalind Advisors, Steven Salamon, …